Charles Greg Guyer Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Charles Greg Guyer is EVP, Chief Technical Officer of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 68,909 shares of BMRN, which is worth approximately $4.52 Million. The most recent transaction as insider was on Nov 12, 2024, when has been sold 5,278 shares (Common Stock) at a price of $66.37 per share, resulting in proceeds of $350,300. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 68.9K

7.05% 3M change

32.48% 12M change

Total Value Held $4.52 Million

Charles Greg Guyer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 12 2024	SELL Open market or private sale	$350,300 $66.37 p/Share	5,278 Reduced 7.11%	68,909 Common Stock
Oct 31 2024	BUY Grant, award, or other acquisition	$3,080 $56.01 p/Share	55 Added 0.07%	74,187 Common Stock
May 03 2024	SELL Payment of exercise price or tax liability	$366,033 $82.44 p/Share	4,440 Reduced 5.65%	74,132 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$16,819 $68.65 p/Share	245 Added 0.31%	78,572 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$1,712,960 $83.87 p/Share	20,424 Reduced 20.68%	78,327 Common Stock
Mar 15 2024	BUY Grant, award, or other acquisition	-	10,550 Added 9.65%	98,751 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	36,187 Added 29.09%	88,201 Common Stock
Dec 01 2023	BUY Grant, award, or other acquisition	-	11,840 Added 18.54%	52,014 Common Stock
Oct 31 2023	BUY Grant, award, or other acquisition	$9,207 $69.23 p/Share	133 Added 0.33%	40,174 Common Stock
Aug 09 2023	SELL Open market or private sale	$500,088 $93.3 p/Share	5,360 Reduced 11.81%	40,041 Common Stock
May 04 2023	SELL Payment of exercise price or tax liability	$410,625 $95.45 p/Share	4,302 Reduced 8.66%	45,401 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$15,984 $66.88 p/Share	239 Added 0.48%	49,703 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$162,845 $87.74 p/Share	1,856 Reduced 3.62%	49,464 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	8,900 Added 14.78%	51,320 Common Stock
Aug 08 2022	SELL Open market or private sale	$599,155 $96.56 p/Share	6,205 Reduced 12.83%	42,168 Common Stock
May 04 2022	SELL Payment of exercise price or tax liability	$332,336 $84.65 p/Share	3,926 Reduced 7.51%	48,373 Common Stock
Apr 29 2022	BUY Grant, award, or other acquisition	$15,166 $62.41 p/Share	243 Added 0.46%	52,299 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$72,008 $78.27 p/Share	920 Reduced 1.74%	52,056 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	11,040 Added 17.25%	52,976 Common Stock
May 04 2021	SELL Payment of exercise price or tax liability	$312,303 $78.35 p/Share	3,986 Reduced 8.73%	41,695 Common Stock
Apr 30 2021	BUY Grant, award, or other acquisition	$13,793 $62.41 p/Share	221 Added 0.48%	45,681 Common Stock
Mar 15 2021	BUY Grant, award, or other acquisition	-	10,420 Added 18.65%	45,460 Common Stock

CGG

Charles Greg Guyer

EVP, Chief Technical Officer

San Rafael, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMRN shares.

Notify only if

Value

Insider Trading

Get notified when an Biomarin Pharmaceutical Inc insider buys or sells BMRN shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOMARIN PHARMACEUTICAL INC

Track Activities on BMRN

Account